Catalog No.
DHF88301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
T1, DER4, Interleukin-1 receptor-like 1, ST2, IL1RL1, Protein ST2
Concentration
0.91 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q01638
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AMG-282, MSTT-1041A, RG-6149, RO-7187807, CAS: 2173054-79-8
Clone ID
Astegolimab
Note
For research use only. Not suitable for clinical or therapeutic use.
Electroacupuncture Protects Against Post-stroke Cognitive Impairment by Promoting an IL-33/ST2 Axis-Mediated Microglia M2 Polarization. [DHF88301]
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial., PMID:33872652
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires., PMID:34346168
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma., PMID:34964491
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial., PMID:35339234
Specific Therapy for T2 Asthma., PMID:35455709
Investigational approaches for unmet need in severe asthma., PMID:35786146
Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis., PMID:36041655
IL-33 antagonism does not improve chronic atopic dermatitis: What can we learn?, PMID:36270492
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial., PMID:36519984
Factors contributing to the nonlinear pharmacokinetics of astegolimab: a close examination of potential causes., PMID:37791725
Mechanistic role of RND3-regulated IL33/ST2 signaling on cardiomyocyte senescence., PMID:38724005
Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins., PMID:38762432
Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials., PMID:39589286
Targeting alarmins in asthma: From bench to clinic., PMID:39855362
Biologic Therapies for Severe Asthma: Current Insights and Future Directions., PMID:40364184
Advancements in Biologic Therapies for Pediatric Asthma: Emerging Therapies and Future Directions., PMID:40486460
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires, PMID: 34346168
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial, PMID: 33872652
For research use only. Not for human or drug use.
